المؤلفون: Yu. G. Belotserkovskaya, A. G. Romanovskikh, I. P. Smirnov, Ю. Г. Белоцерковская, А. Г. Романовских, И. П. Смирнов

المصدر: Meditsinskiy sovet = Medical Council; № 18 (2022); 122-130 ; Медицинский Совет; № 18 (2022); 122-130 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: порошковый ингалятор, COVID-19 and Asthma, Single Inhaler Maintenance and Reliever Therapy, budesonide/ formoterol, dry powder inhaler, COVID-19 и бронхиальная астма, режим единого ингалятора, будесонид/формотерол

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7130/6402; To T., Stanojevic S., Moores G., Gershon A.S., Bateman E.D., Cruz A.A., Boulet L.P. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;(12):204. https://doi.org/10.1186/1471-2458-12-204.; Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x.; Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0.; Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2.; Cisneros Serrano C., Melero Moreno C., Almonacid Sánchez C., Perpiñá Tordera M., Picado Valles C., Martínez Moragón E. et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–246. https://doi.org/10.1016/j.arbres.2014.12.007.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.; Corne J.M., Marshall C., Smith S., Schreiber J., Sanderson G., Holgate S.T., Johnston S.L. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–834. https://doi.org/10.1016/S0140-6736(02)07953-9.; Jackson D.J., Trujillo-Torralbo M.B., del-Rosario J., Bartlett N.W., Edwards M.R., Mallia P. et al. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015;136(2):497–500. https://doi.org/10.1016/j.jaci.2015.01.028.; Sykes A., Edwards M.R., Macintyre J., del Rosario A., Bakhsoliani E., Trujillo- Torralbo M.B. et al. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012;129(6):1506–1514. https://doi.org/10.1016/j.jaci.2012.03.044.; Wark P.A., Johnston S.L., Bucchieri F., Powell R., Puddicombe S., Laza- Stanca V. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947. https://doi.org/10.1084/jem.20041901.; Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026. https://doi.org/10.1038/nm1462.; Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7.; Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. https://doi.org/10.1016/j.jaci.2020.04.006.; Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K. COVID-19 in critically ill patients in the Seattle region – case series. N Engl J Med. 2020;(382):2012–2022. https://doi.org/10.1056/NEJMoa2004500.; Garg S., Kim L., Whitaker M., O`Halloran A., Cummings C., Holstein R. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. https://doi.org/10.15585/mmwr.mm6915e3.; Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195–2198. https://doi.org/10.1001/jama.2020.7202.; Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–314. https://doi.org/10.1016/j.jaci.2020.06.010.; Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2.; Yang M., Zhang Y., Chen H., Lin J., Zeng J., Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection. 2019;47(3):377–385. https://doi.org/10.1007/s15010-018-1229-y.; Yang M., Chen H., Zhang Y., Du Y., Xu Y., Jiang P., Xu Z. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29(5):219–226. https://doi.org/10.1080/08958378.2017.1346006.; Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7):CD002991. https://doi.org/10.1002/14651858.; Contoli M., Pauletti A., Rossi M.R., Spanevellj A., Casolari P., Marcellina A. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. https://doi.org/10.1183/13993003.00451-2017.; Yamaya M., Nishimura H., Deng X., Sugawara M., Watanabe O., Nomura K. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. https://doi.org/10.1016/j.resinv.2019.12.005.; Matsuyama S., Kawase M., Nao N., Shirato K., Ujike M., Kamitani W. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. https://doi.org/10.1101/2020.03.11.987016.; Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. https://doi.org/10.1128/AAC.00819-20.; Jackson D.J., Busse W.W., Bacharier L.B., Kattan M., O`Connor G.T., Wood R.A. et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020;146(1):203–206. https://doi.org/10.1016/j.jaci.2020.04.009.; Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19 related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83–90. https://doi.org/10.1164/rccm.202003-0821OC.; Yang J.M., Koh H.Y., Moon S.Y., Yoo I.K., Ha E.K., You S. et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–798. https://doi.org/10.1016/j.jaci.2020.08.008.; Mahdavinia M., Foster K.J., Jauregui E., Andy-Nweye A.B., Khan S. et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2388–2391. https://doi.org/10.1016/j.jaip.2020.05.006.; Caminati M., Vultaggio A., Matucci A., Vianello A., Vivarelli E., Crisafulli E. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;(176)106261. https://doi.org/10.1016/j.rmed.2020.106261.; Sobieraj D.M., Weeda E.R., Nguyen E., Coleman C.I., White C.M., Lazarus S.C. et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496. https://doi.org/10.1001/jama.2018.2769.; Rogliani P., Ritondo B.L., Ora J., Cazzola M., Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020;56(3):2000625. https://doi.org/10.1183/13993003.00625-2020.; Beasley R., Harrison T., Peterson S., Gustafson P., Hamblin A., Bengtsson T., Fageras M. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma. A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. https://doi.org/10.1001/jamanetworkopen.2022.0615.; Bush A. Severe and Difficult Asthma: Diagnosis and ManagementChallenges for a Low-Resource Environment. Indian J Pediatr. 2022;89(2):156–162. https://doi.org/10.1007/s12098-021-03952-w.; Hodder R. The paradox of adult asthma control: “Who’s in control anyway?” Can Respir J. 2007;14(4):229–234. https://doi.org/10.1155/2007/975134.; Molimard M., Raherison C., Lignot M., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–254. https://doi.org/10.1089/089426803769017613.; Lavorini F., Magnan A., Dubus J.C., Voshaar T., Corbetta L., Broeders M. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604. https://doi.org/10.1016/j.rmed.2007.11.003.; Dudvarski Ilic A., Zugic V., Zvezdin B., Kopitovic I., Cekerevac I., Cupurdija V. et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Obstruct Pulmon Dis. 2016;(11):2509–2517. https://doi.org/10.2147/COPD.S114576.; Игнатова Г.Л., Белевский А.С. Современные способы ингаляционной доставки лекарств при лечении бронхообструктивных заболеваний. Астма и аллергия. 2018;(2):21–28. Режим доступа: https://atmosphere-ph.ru/modules.php?name=Magazines&sop=viewissue&magid=2&issueid=442.; Визель А.А., Белевский А.С., Визель И.Ю. К лечению бронхиальной астмы и хронической обструктивной болезнью легких: идем вперед с проверенными молекулами. Лечебное дело. 2020;(2):59–64. https://doi.org/10.24411/2071-5315-2020-12212.; Emeryk А., Pirożyński M., Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018;86(1):44–52. https://doi.org/10.5603/ARM.2017.0061.; https://www.med-sovet.pro/jour/article/view/7130

الاتاحة: https://www.med-sovet.pro/jour/article/view/7130
https://doi.org/10.21518/2079-701X-2022-16-18-122-130